Condition: Type I Diabetes · Sponsor: Op-T LLC
This study will examine the safety of three times weekly SC injections of OPT101 at each of three dose levels over two weeks as well as one year of treatment with SC OPT101 or placebo to match at a single dose level.
This description comes directly from the study's public registry record.
Lisa Boswell · 303-503-9954 · lb@op-t.com
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham - Department of Medicina | Birmingham, Alabama, United States | Recruiting |
| Diablo Clinical Research Center | Walnut Creek, California, United States | Recruiting |
| Barbara Davis Center - University of Colorado Anschuttz Medical Campus | Aurora, Colorado, United States | Recruiting |
| University of Chicago Medical Center | Chicago, Illinois, United States | Recruiting |
| Rainier Clinical Research Center | Renton, Washington, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06964087